Zobrazeno 1 - 10
of 50
pro vyhledávání: ''
Autor:
Pochon, Susan1
Publikováno v:
American Journal of Cancer. Jul2005, Vol. 4 Issue 4, p275-278. 4p. 1 Chart.
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
Gückel, Brigitte, Stumm, Susanne, Rentzsch, Christine, Marmé, Alexander, Mannhardt, Geeske, Wallwiener, Diethelm
Publikováno v:
Cancer Immunology, Immunotherapy; Feb2005, Vol. 54 Issue 2, p129-140, 12p
Autor:
Tokuda, Yntaka
Publikováno v:
International Journal of Clinical Oncology; Aug2003, Vol. 8 Issue 4, p224-229, 6p
Publikováno v:
PharmacoEconomics & Outcomes News. 3/27/2004, Issue 449, p5-5. 3/5p. 1 Chart.
Autor:
Qiongchao Jiang, Bing Ou, Fengtao Liu, Jiyi Yao, Hui Zhi, Shao-Yun Hao, Xin Pan, Xiao-yun Xiao, Zizhuo Zhao, Bao-Ming Luo
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background There is an unmet need for specific and sensitive imaging techniques to assess the efficacy of breast cancer therapy, particularly Her-2-expressing cancers. Ultrasonic microbubbles are being developed for use as diagnostic and therapeutic
Autor:
Oumar Camara, Carola Rabenstein, Cornelia Jörke, Klaus Hoeffken, Ingo B. Runnebaum, Katharina Pachmann, Anne Egbe, U. Hammer
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135(4):643-647
In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many
Autor:
David Miles, José Baselga, Sandra M. Swain, Adam Knott, Graham Ross, Dino Amadori, Patrapim Sunpaweravong, Emma Clark, Vladimir Semiglazov
Publikováno v:
Breast Cancer Research and Treatment
Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conduc
Autor:
Mel Fox, Gary C. Starling, Mian Su, Sonia Tanlimco, Debra Chao, Shiming Ye, Donghee Choi, Johnny Yin, Lisa Durkin, Patricia Culp, Yongke Zhang, Eric D. Hsi, Mien Sho, Han Kim
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background The receptor for the cytokine TWEAK (TweakR) is a cell surface member of the tumor necrosis factor receptor superfamily with diverse biological roles. TNFRSF family members are appealing therapeutic targets in oncology due to their aberran
Autor:
Roy Nitulescu, Tripthi Kamath, Marjolaine Gauthier-Loiselle, Annie Guerin, Anthony Masaquel, Kenneth More, Raluca Ionescu-Ittu, Nicholas Sicignano, Brian Barnett, Christopher Gallagher, Elizabeth Butts, Eric Q. Wu
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzu